XENON PHARMACEUTICALS INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $0 | $0 | $9.4M | $18.4M | $32.2M | $6.8M | $311.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $300.9M | $210.4M | $167.5M | $105.8M | $75.5M | $50.5M | $38.8M | $25.6M |
| SG&A Expense | $79.6M | $68.9M | $46.5M | $32.8M | $22.0M | $12.9M | $10.8M | $7.3M |
| Operating Income | $-373.1M | $-279.3M | $-214.1M | $-129.1M | $-79.0M | $-31.3M | $-42.8M | $-32.6M |
| Operating Margin | -4,974.3% | — | — | -1,368.9% | -428.4% | -97.3% | -627.0% | -10,474.3% |
| Interest Expense | — | — | — | — | — | $484.0K | $1.4M | — |
| Pretax Income | $-344.9M | $-238.4M | $-182.7M | $-125.3M | $-78.9M | $-29.1M | $-41.6M | — |
| Income Tax Expense | $1.0M | $-4.1M | $-292.0K | $118.0K | $-6.0K | $-257.0K | $-23.0K | — |
| Net Income | $-345.9M | $-234.3M | $-182.4M | $-125.4M | $-78.9M | $-28.8M | $-41.6M | $-30.7M |
| Net Margin | -4,612.1% | — | — | -1,328.9% | -427.8% | -89.7% | -609.1% | -9,872.7% |
| EPS (Basic) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 | $-0.81 | $-1.54 | $-1.71 |
| EPS (Diluted) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 | $-0.81 | $-1.54 | $-1.72 |
| Shares Outstanding (Basic) | 79.3M | 77.9M | 66.9M | 60.5M | 43.6M | 34.5M | 28.1M | 18.0M |
| Shares Outstanding (Diluted) | 79.3M | 77.9M | 66.9M | 60.5M | 43.6M | 34.5M | 28.1M | 18.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |